Stockreport

Five Prime Therapeutics Presents Updated Data From the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress

FIVE PRIME THERAPEUTICS  (FPRX) 
Last five prime therapeutics earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.fiveprime.com/investor-relations
PDF - Results Provide First Clinical Demonstration of B7-H4 as a Potential Therapeutic Target and Continue to Support FPA150’s Greatest Potential in Combination Therapy - [Read more]